imara, inc


Intraday Data provided by FACTSET and subject to terms of use. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.

To qualify for Orphan Drug designation in the European Union (EU), an investigational medicine must be intended to treat a seriously debilitating or life-threatening condition that affects fewer than five in 10,000 people in the EU, and there must be sufficient non-clinical or clinical data to suggest the investigational medicine may produce clinically relevant outcomes. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635. Imara, Inc.

I look forward to leading Guy's and St Thomas' participation in this important clinical trial. Attendi un minuto prima di commentare di nuovo. The Company currently expects that its full-year 2020 research and development expenses will range between $35 million and $40 million and that its full-year 2020 general and administrative expenses will range between $8 million and $10 million. We also reported encouraging Phase 2a interim clinical trial results with IMR-687 at the European Hematology Association Annual Congress and more recently observed promising clinical outcomes with longer duration IMR-687 treatment as part of our Phase 2a open label extension trial. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. La tua possibilità di commentare è stata sospesa per via di report negativi da parte di altri utenti. by The Fold, Keep your ear to the ground with our FREE newsletter including our watch list, weekly review and daily updates, Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Lower levels of cGMP are found in people with SCD and beta-thalassemia and are associated with reduced blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation. IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD. Media Contact:Gina Nugent Ten Bridge Communications 617-460-3579 [email protected] Investor Contact:Michael Gray617-835-4061[email protected]. BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first patient in the company's Ardent Phase 2b clinical trial of IMR-687 for adult patients with sickle cell disease (SCD).

Cookie Notice. For more information about the Ardent trial visit https://clinicaltrials.gov/ct2/show/NCT04474314?cond=Imr-687&draw=2&rank=3.
ET to discuss its second quarter 2020 financial results and other business updates. Evita bestemmie, calunnie e gli attacchi personali rivolti. Imara sets IPO terms, expects to raise up to $80 million and be valued at up to $294 million, Biotech IPOs Sail Through Coronavirus Storm, 4 Stocks to Keep an Eye on as Analysts Initiate Coverage, Repare and Forma Shares Gobbled Up in IPO, HTZ, GLYC, NVCN and SELB among midday movers, Imara reports positive IMR-687 data in sickle cell disease, Imara under pressure on underwhelming data in IMR-687 in sickle cell disease, Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO, IPO Update: Imara Readies $76 Million U.S. IPO, Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia, Imara Added to Membership of U.S. Small-Cap Russell 2000(R) Index, Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders, Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia, Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress, Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress, Imara Reports First Quarter 2020 Financial Results and Business Highlights, Imara Launches 'Real Impact' Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders, Imara Announces Appointment of Stephen M. Migausky as General Counsel, Flexible Fuel Tank Sales Market 2020 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2026. These statements include, but are not limited to, the statements from Dr. Howard and Dr. Ballal in this press release and statements relating to the (i) expected timing for reporting of data from the ongoing Phase 2a clinical trial evaluating IMR-687 in patients with sickle cell disease and (iii) the Company's beliefs regarding the strength of its clinical data, the therapeutic potential of IMR-687 and advancement of its clinical program, including with respect to the Phase 2b clinical trial evaluating IMR-687 in patients with sickle cell disease, the Phase 2a clinical trial evaluating IMR-687 in patients with sickle cell disease and the open label extension to the  Phase 2a clinical trial. “We are pleased to have received Orphan Drug designation from the European Commission, reinforcing the unmet need for more effective treatment options for patients with sickle cell disease, a rare blood disorder characterized by debilitating pain, progressive multi-organ damage and early death,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. (1)   Working capital is defined as current assets less current liabilities. BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to …


About IMR-687 IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. We operate directly and through partners in 10 African countries, as well as an office in London. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. In addition, the company has an ongoing open label extension (OLE) clinical trial, which allows patients from the Phase 2a clinical trial to continue into a long-term, four-year trial to evaluate safety and tolerability of IMR-687.

We believe that this increased exposure could have a meaningful impact on the therapeutic effect of IMR-687 on patients enrolled in this trial.

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the Company will participate in the following upcoming virtual investor conferences in September: A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.